163 related articles for article (PubMed ID: 23337981)
1. Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus.
Moussavi M; Tearle H; Fazli L; Bell JC; Jia W; Rennie PS
Mol Ther; 2013 Apr; 21(4):842-8. PubMed ID: 23337981
[TBL] [Abstract][Full Text] [Related]
2. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice.
Moussavi M; Fazli L; Tearle H; Guo Y; Cox M; Bell J; Ong C; Jia W; Rennie PS
Cancer Res; 2010 Feb; 70(4):1367-76. PubMed ID: 20145134
[TBL] [Abstract][Full Text] [Related]
3. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.
Urbiola C; Santer FR; Petersson M; van der Pluijm G; Horninger W; Erlmann P; Wollmann G; Kimpel J; Culig Z; von Laer D
Int J Cancer; 2018 Oct; 143(7):1786-1796. PubMed ID: 29696636
[TBL] [Abstract][Full Text] [Related]
5. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
Ahmed M; Cramer SD; Lyles DS
Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
[TBL] [Abstract][Full Text] [Related]
9. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
Shulak L; Beljanski V; Chiang C; Dutta SM; Van Grevenynghe J; Belgnaoui SM; Nguyên TL; Di Lenardo T; Semmes OJ; Lin R; Hiscott J
J Virol; 2014 Mar; 88(5):2927-40. PubMed ID: 24371063
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
Cary ZD; Willingham MC; Lyles DS
J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
[TBL] [Abstract][Full Text] [Related]
12. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
[TBL] [Abstract][Full Text] [Related]
13. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
[TBL] [Abstract][Full Text] [Related]
15. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
16. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
17. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.
Wollmann G; Davis JN; Bosenberg MW; van den Pol AN
J Virol; 2013 Jun; 87(12):6644-59. PubMed ID: 23552414
[TBL] [Abstract][Full Text] [Related]
18. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]